| 0.8496 Data as of 3:59pm ET |  -0.0645 / -7.06%Today’s Change | 0.37 Today|||52-Week Range 2.27 | +95.31% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $37.9M |
Company Description
Catalyst Pharmaceutical Partners, Inc. is a development stage biopharmaceutical company, which focuses on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The company has two products in development, and is currently evaluating its lead product GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin) for the treatment of cocaine addiction and it also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst Pharmaceutical Partners also develops CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects from those associated with vigabatrin. The company is planning to develop CPP-115 for several indications, including drug addiction, epilepsy and for use in the reduction or elimination of addictive liability in the treatment of pain. It was founded by McEnany J. Patrick and Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
Employees
Shareholders
| Individual stakeholders | 31.07% |
| Mutual fund holders | 11.34% |
| Other institutional | 1.87% |
Top Executives
| Patrick J. McEnany | Chairman, President & Chief Executive Officer |
| Steven R. Miller, PhD | Chief Operating & Scientific Officer |
| Alicia Grande, CPA | Chief Financial Officer, Treasurer & VP |
| Charles W. Gorodetzky, MD, PhD | Chief Medical Officer |
| Hubert E. Huckel, MD | Independent Director |
.
